Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-75dct Total loading time: 0 Render date: 2024-06-12T12:50:08.490Z Has data issue: false hasContentIssue false

Chapter 18 - Clozapine: an effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospital

from Section 5 - Psychopharmacology

Published online by Cambridge University Press:  19 October 2021

By
Darcy Brown ,
Fintan Larkin ,
Samrat Sengupta ,
Jose L. Romero-Ureclay ,
Callum C. Ross ,
Nitin Gupta ,
Morris Vinestock  and
Mrigendra Das
Edited by
Katherine D. Warburton  and
Stephen M. Stahl
Katherine D. Warburton
Affiliation:
University of California, Davis
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Violence in Psychiatry , pp. 187 - 201
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ingenhoven, T, Lafay, P, Rinne, T, et al. Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J. Clin. Psychiatry. 2010; 71(1): 14–25.Google Scholar
Lieb, K, Völlm, B, Rücker, G, et al. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br. J. Psychiatry. 2010; 196(1): 4–12.CrossRefGoogle ScholarPubMed
Stoffers, JBA, Vo¨llm, G, Ru¨cker, A, et al. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev. 2010; (6): CD005653.CrossRefGoogle Scholar
Bellino, S, Paradiso, E, Bogetto, F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study. J. Clin. Psychiatry. 2006; 67(7): 1042–1046.CrossRefGoogle ScholarPubMed
Hilger, E, Barnas, C, Kasper, S. Quetiapine in the treatment of borderline personality disorder. World J. Biol. Psychiatry. 2003; 4(1): 42–44.Google Scholar
Villeneuve, E, Lemelin, S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J. Clin. Psychiatry. 2005; 66(10): 1298–1303.Google Scholar
Nickel, M, Muehlbacher, M, Nickel, C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am. J. Psychiatry. 2006; 163(5): 833–838.CrossRefGoogle ScholarPubMed
Bellino, S, Bozzatello, P, Rinaldi, C, Bogetto, F. Paliperidone ER in the treatment of borderline personality disorder: a pilot study of efficacy and tolerability. Depress. Res. Treat. 2011; 2011: 680194.Google Scholar
Grootens, KP, Verkes, RJ. Emerging evidence for the use of atypical antipsychotics in borderline personality disorder. Pharmacopsychiatry. 2005; 38(01): 20–23.CrossRefGoogle ScholarPubMed
Bogenschutz, MP, Nurnberg, G. Olanzapine versus placebo in the treatment of borderline personality disorder. J. Clin. Psychiatry. 2004; 65(1): 104–109.Google Scholar
Linehan, MM, McDavid, JD, Brown, MZ, Sayrs, JH, Gallop, RJ. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J. Clin. Psychiatry. 2008; 69(6): 999–1005.Google Scholar
Schulz, CS, Camlin, KL, Berry, SA, Jesberger, JA. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol. Psychiatry. 1999; 46(10): 1429–1435.Google Scholar
Zanarini, MC, Frankenburg, FR, Parachini, EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine–fluoxetine combination in women with borderline personality disorder. J. Clin. Psychiatry. 2004; 65(7): 903–907.Google Scholar
Zanarini, MC, Frankenburg, FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo controlled pilot study. J. Clin. Psychiatry. 2001; 62(11): 849–854.Google Scholar
Keshavan, M, Shad, M, Soloff, P, Schooler, N. Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder. Schizophr. Res. 2004; 71(1): 97–101.CrossRefGoogle ScholarPubMed
Koenigsberg, HW, Reynolds, D, Goodman, M, et al. Risperidone in the treatment of schizotypal personality disorder. J. Clin. Psychiatry. 2003; 64(6): 628–634.CrossRefGoogle ScholarPubMed
Rocca, P, Marchiaro, L, Cocuzza, E, Bogetto, F. Treatment of borderline personality disorder with risperidone. J. Clin. Psychiatry. 2002; 63(3): 241–244.Google Scholar
Vauquelin, G, Bostoen, S, Vanderheyden, P, Seeman, P. Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism. Naunyn Schmiedebergs Arch. Pharmacol. 2012; 385(4): 337–372.Google Scholar
Fakra, E, Azorin, J. Clozapine for the treatment of schizophrenia. Expert Opin. Pharmacother. 2012; 13(3): 1923–1935.Google Scholar
Chakos, M, Lieberman, J, Hoffman, E, Bradford, D, Sheitman, B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry. 2001; 158(4): 518–526.CrossRefGoogle ScholarPubMed
Kane, J, Honigfeld, G, Singer, J, Meltzer, H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 1988; 45(9): 789–796.Google Scholar
Meltzer, Herbert Y. Treatment-resistant schizophrenia-the role of clozapine. Curr. Med. Res. Opin. 1997; 14(1): 1–20.Google Scholar
Chengappa, KN, Ebeling, T, Kang, JS, Levine, J, Parepally, H. Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J. Clin. Psychiatry. 1999; 60(7): 477–484.CrossRefGoogle ScholarPubMed
Vohra, AK. Treatment of severe borderline personality disorder with clozapine. Indian J. Psychiatry. 2010; 52(3): 267–269.CrossRefGoogle ScholarPubMed
Benedetti, F, Sforzini, L, Colombo, C, Maffei, C, Smeraldi, E. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J. Clin. Psychiatry. 1998; 59(3): 103–107.CrossRefGoogle ScholarPubMed
Swinton, M. Clozapine in severe borderline personality disorder. The Journal of Forensic Psychiatry. 2001; 12(3): 580–591.Google Scholar
Frankenburg, FR, Zanarini, MC. Clozapine treatment of borderline patients: a preliminary study. Compr. Psychiatry. 1993; 34(6): 402–405.Google Scholar
Buckley, P, Bartell, J, Donenwirth, K, et al. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull. Am. Acad. Psychiatry Law. 1995; 23(4): 607–611.Google Scholar
Frogley, C, Taylor, D, Dickens, G, Picchioni, M. A systematic review of the evidence of clozapine’s anti-aggressive effects. Int. J. Neuropsychopharmacol. 2012; 15(9): 1351–1371.Google Scholar
Chengappa, KNR, Vasile, J, Levine, J, et al. Clozapine: its impact on aggressive behaviour among patients in a state psychiatric hospital. Schizophr. Res. 2002; 53(1–2): 1–6.CrossRefGoogle Scholar
Citrome, L, Volavka, J, Czobor, P, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr. Serv. 2001; 52(11): 1510–1514.Google Scholar
Dalal, B, Larkin, E, Leese, M, Taylor, PJ. Clozapine treatment of longstanding schizophrenia and serious violence: a two-year follow-up study of the first 50 patients treated with clozapine in Rampton high security hospital. Crim. Behav. Ment. Health. 1999; 9(2): 168–178.Google Scholar
Rabinowitz, J, Avnon, M, Rosenberg, V. Effect of clozapine on physical and verbal aggression. Schizophr. Res. 1996; 22(3): 249–255.CrossRefGoogle ScholarPubMed
Ratey, JJ, Leveroni, C, Kilmer, D, Gutheil, C. The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. J. Clin. Psychiatry. 1993; 54(6): 219–223.Google Scholar
Volavka, J. The effects of clozapine on aggression and substance abuse in schizophrenic patients. J. Clin. Psychiatry. 1999; 60(Suppl 12): 43–46.Google Scholar
Krakowski, MI, Czobor, P, Citrome, L, Bark, N, Cooper, TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry. 2006; 63(6): 622–629.Google Scholar
Hare, RD. Manual for the Revised Psychopathy Checklist (1st edn). 1991. Toronto, ON, Canada: Multi-Health Systems. URL for other refs: http://scholar.google.co.uk/scholar?hl5en&q5hare1checklist& btnG5&as_sdt51%2C5&as_sdtp5Google Scholar
Hart, SD, Cox, DN, Hare, RD. The Hare Psychopathy Checklist: Screening Version (PCL: SV). Toronto, ON, Canada: Multi-HealthSystems, Inc.; 1995.Google Scholar
Guy, W. The Clinical Global Impression Scale. In: Guy, W, ed. ECDEU Assessment Manual for Psychopharmacology. Rev. edn. Rockville, MD: U.S. Department of Health, Education and Welfare, ADAMHA, MIMH Psychopharmacology Research Branch; 1976:218–222.Google Scholar
Frankenburg, FR, Zanarini, MC. Clozapine treatment of borderline patients: a preliminary study. Compr. Psychiatry. 1993; 34(6): 402–405.Google Scholar
Binks, CA, Fenton, M, McCarthy, L, et al. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst. Rev. 2006; (1): CD005652.Google Scholar
Soloff, PH. Algorithms for pharmacological treatment of personality dimensions: symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioural dysregulation. Bull. Menninger Clin. 1997; 62(2): 195–214.Google Scholar
Webster, C, Douglas, K, Eaves, D, Hart, S. HCR-20: Assessing Risk for Violence. Version 2; 1992. Burnaby, BC, Canada: Mental Health, Law and Policy Institute, Simon Fraser University.Google Scholar
World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization; 1992; 50.Google Scholar
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn, text rev. Washington, DC: American Psychiatric Association; 2000.Google Scholar
Glazer, GM, Dickson, RA. Clozapine reduces violence and persistent aggression in schizophrenia. J. Clin. Psychiatry. 1998; 59(Suppl 3): 8–14.Google Scholar
Spina, E, Avenoso, A, Facciol`a, G, et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl.). 2000; 148(1): 83–89.Google Scholar
Humbert-Claude, M, Davenas, E, Gbahou, F, Vincent, L, Arrang, JM. Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo. Psychopharmacology (Berl.). 2012; 220(1): 225–241.CrossRefGoogle ScholarPubMed
Stahl, SM. Psychopharmacology of Antipsychotics. London: Martin Dunitz; 1999.Google Scholar
Harrison, AA, Everitt, BJ, Robbins, TW. Central 5-HT depletion enhances impulsive responding without affecting the accuracy of attentional performance: interactions with dopaminergic mechanisms. Psychopharmacology (Berl.). 1997; 133(4): 329–342.Google Scholar
Vukhac, K, Sankoorika, EL, Yanyan Wang. Dopamine D2L receptor and age-related reduction in offensive aggression. Neuroreport. 2001; 12(5): 1035–1038.Google Scholar
Wade, TR, Wit, HD, Richards, JB. Effects of dopaminergic drugs on delayed reward as a measure of impulsive behaviour in rats. Psychopharmacology (Berl.). 2000; 150(1): 90–101.Google Scholar
Chotai, J, Kullgren, J, Åsberg, M. CSF monoamine metabolites in relation to the diagnostic interview for borderline patients (DIB). Neuropsychobiology. 1998; 38(4): 207–212.CrossRefGoogle Scholar
Coccaro, EF, Silk, KR, ed. Neurotransmitter function in personality disorders. In: Biology of Personality Disorders. Washington, DC: American Psychiatric Press; 1998: 1–25.Google Scholar
Friedel, RO. Dopamine dysfunction in borderline personality disorder: a hypothesis. Neuropsychopharmacology. 2004; 29(6): 1029–1039.Google Scholar
Adams, DB. Brain mechanisms for offence, defence, and submission. Behav. Brain Sci. 1979; 2(2): 201–213.CrossRefGoogle Scholar
Berman, ME, Tracy, JI, Coccaro, EF. The serotonin hypothesis of aggression revisited. Clin. Psychol. Rev. 1997; 17(6): 651–665.CrossRefGoogle ScholarPubMed
Brown, GL. Aggression, suicide, and serotonin: relationships of CSF amine metabolites. Am. J. Psychiatry. 1982; 139(6): 741–746.Google Scholar
de Boer, FS, Koolhaas, JM. 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis. Eur. J. Pharmacol. 2005; 526(1–3): 125–139.Google Scholar
Gowin, JL, Swann, AC, Moeller, FG, Lane, SD. Zolmitriptan and human aggression: interaction with alcohol. Psychopharmacology (Berl.). 2010; 210(4): 521–531.Google Scholar
Miczek, KA, Fish, EW, Joseph, F, De Almeida, RM. Social and neural determinants of aggressive behaviour: pharmacotherapeutic targets at serotonin, dopamine and γ-aminobutyric acid systems. Psychopharmacology (Berl.). 2002; 163(3): 434–458.Google Scholar
Moss, HB, Yao, JK, Panzak, GL. Serotonergic responsivity and behavioral dimensions in antisocial personality disorder with substance abuse. Biol. Psychiatry. 1990; 28(4): 325–338.Google Scholar
Constantino, JN, Morris, JA, Murphy, DL. CSF 5-HIAA and family history of antisocial personality disorder in newborns. Am. J. Psychiatry. 1997; 154(2): 1771–1773.CrossRefGoogle ScholarPubMed
Krakowski, M. Violence and serotonin: influence of impulse control, affect regulation, and social functioning. J Neuropsychiatry Clin Neurosci. 2003; 15(3): 294–305.Google Scholar
Umukoro, S, Aladeokin, AC, Eduviere, AT. Aggressive behavior: a comprehensive review of its neurochemical mechanisms and management. Aggression and Violent Behavior. 2012; 18(2): 195–203.CrossRefGoogle Scholar
Paris, P. Antisocial and borderline personality disorders: two separate diagnoses or two aspects of the same psychopathology? Compr. Psychiatry. 1997; 38(4): 237–242.CrossRefGoogle ScholarPubMed
Bateman, AW, Tyrer, P. Psychological treatment for personality disorders. Advances in Psychiatric Treatment. 2004; 10(5): 378–388.Google Scholar
Bellino, S, Paradiso, E, Bogetto, F. Efficacy and tolerability of pharmacotherapies for borderline personality disorder. CNS Drugs. 2008; 22(8): 671–692.Google Scholar
Nelson, KJ, Schulz, CS. Treatment advances in borderline personality disorder. Psychiatric Annals. 2012; 42(2): 59–64.Google Scholar
Dolan, M. Psychopathic personality in young people. Advances in Psychiatric Treatment. 2004; 10(6): 466–473.Google Scholar
Hare, RD. Psychopathy, affect and behaviour. In: Cooke, DJ, Forth, AE, Hare, RD, eds. Psychopathy: Theory, Research and Implications for Society. Dordrecht, the Netherlands: Springer; 1998: 105–137.Google Scholar
Salekin, RT, Rogers, R, Sewell, KW. A review and meta-analysis of the Psychopathy Checklist and Psychopathy Checklist-Revised: predictive validity of dangerousness. Clinical Psychology: Science and Practice. 1996; 3(3): 203–215.Google Scholar
Buckholtz, JW, Treadway, MT, Cowan, RL, et al. Mesolimbic dopamine reward system hypersensitivity in individuals with psychopathic traits. Nat. Neurosci. 2010; 13(4): 419–421.Google Scholar
Dolan, MC, Anderson, IM. The relationship between serotonergic function and the Psychopathy Checklist: Screening Version. J. Psychopharmacol. 2003; 17(2): 216–222.CrossRefGoogle ScholarPubMed
Soderstrom, H, Blennow, K, Sjodin, AK, Forsman, A. New evidence for an association between the CSF HVA:5-HIAA ratio and psychopathic traits. J. Neurol. Neurosurg. Psychiatry. 2003; 74(7): 918–921.Google Scholar
Barkataki, I, Kumar, V, Das, M, Taylor, P, Sharma, T. Volumetric structural brain abnormalities in men with schizophrenia or antisocial personality disorder. Behav. Brain Res. 2006; 169(2): 239–247.Google Scholar
Kumari, V, Das, M, Taylor, PJ, et al. Neural and behavioural responses to threat in men with a history of serious violence and schizophrenia or antisocial personality disorder. Schizoph. Res. 2009; 110(1–3): 47–58.Google Scholar
Yang, Y, Raine, R. Prefrontal structural and functional brain imaging findings in antisocial, violent, and psychopathic individuals: a meta-analysis. Psychiatry Res. 2009; 174(2): 81–88.Google Scholar
Chopra, HD, Beatson, JA. Psychotic symptoms in borderline personality disorder. Am. J. Psychiatry. 1986; 143(12): 1605–1607.Google Scholar
Kendal, T, Pilling, S, Tyrer, P, et al. Guidelines: Borderline and Antisocial Personality Disorders: Summary of NICE Guidance. BMJ. 2009; 338(7689): 293–295.Google Scholar
Volavka, J, Citrome, L. Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns. Schizophr. Res. 1999; 35(Suppl): S23–S33.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×